PE20231436A1 - Inhibidores de la secrecion de proteinas - Google Patents
Inhibidores de la secrecion de proteinasInfo
- Publication number
- PE20231436A1 PE20231436A1 PE2023000533A PE2023000533A PE20231436A1 PE 20231436 A1 PE20231436 A1 PE 20231436A1 PE 2023000533 A PE2023000533 A PE 2023000533A PE 2023000533 A PE2023000533 A PE 2023000533A PE 20231436 A1 PE20231436 A1 PE 20231436A1
- Authority
- PE
- Peru
- Prior art keywords
- 6alkyl
- halo
- present
- independently
- 6alkoxy
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 230000028327 secretion Effects 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- -1 C(O)N(RN)2 Chemical group 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101100476756 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) sec-61 gene Proteins 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Referido a un compuesto, o una sal farmaceuticamente aceptable de este, que tiene una estructura de Formula (I) o (I'), en donde R1 es H, C1-3alquilo, o SO2C1-6alquilo; cada uno de X e Y es independientemente N o CRC; el anillo A es un heteroarilo de 6 miembros con 2 atomos de N en el anillo; RA es H, C1-6alquilo, ORN, N(RN)2, OC1-6alquileno-N(RN)2, o OC1-6alquileno-ORN; RB es C1-6alquilo, C1-6alkoxi, C1-3alquileno-C1-3alkoxi, entre otros; m es 1 o 2; cada RC es independientemente H, halo, C1-6alkoxi, N(RN)2, CN, Het, o C1-6alquilo; n es 0, 1, o 2; cada RD, cuando esta presente, es independientemente halo, C1-6alkoxi, o C1-6alquilo; cada Rx, cuando esta presente, es independientemente halo o C1-6alquilo; p es 0 o 1; Ry, cuando esta presente, es C1-6alquilo o halo; o es 0 o 1; Rz, cuando esta presente, es CN, halo, C(O)N(RN)2, C1-6alquilo, entre otros. Estos compuestos son inhibidores de la secrecion de proteinas, tales como inhibidores de Sec61; tambien se refiere a metodos para su preparacion, composiciones farmaceuticas de los mismos y su uso en el tratamiento del cancer, melanoma, mieloma multiple, cancer de prostata, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063072690P | 2020-08-31 | 2020-08-31 | |
| PCT/US2021/048317 WO2022047347A1 (en) | 2020-08-31 | 2021-08-31 | Protein secretion inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231436A1 true PE20231436A1 (es) | 2023-09-14 |
Family
ID=78087485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000533A PE20231436A1 (es) | 2020-08-31 | 2021-08-31 | Inhibidores de la secrecion de proteinas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230286973A1 (es) |
| EP (1) | EP4204417A1 (es) |
| JP (1) | JP2023539553A (es) |
| KR (1) | KR20230058655A (es) |
| CN (1) | CN116194455A (es) |
| AR (1) | AR123385A1 (es) |
| AU (1) | AU2021334388A1 (es) |
| BR (1) | BR112023003265A2 (es) |
| CA (1) | CA3190441A1 (es) |
| CL (1) | CL2023000582A1 (es) |
| CO (1) | CO2023002202A2 (es) |
| IL (1) | IL300736A (es) |
| MX (1) | MX2023002288A (es) |
| PE (1) | PE20231436A1 (es) |
| TW (1) | TW202227428A (es) |
| WO (1) | WO2022047347A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR128634A1 (es) * | 2022-02-28 | 2024-05-29 | Kezar Life Sciences | Inhibidores de sec61 y uso de los mismos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| WO2019046668A1 (en) * | 2017-08-31 | 2019-03-07 | Kezar Life Sciences | AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN |
| MX2021010314A (es) * | 2019-02-28 | 2021-11-12 | Kezar Life Sciences | Derivados de tiazol como inhibidores de la secreción de proteínas. |
-
2021
- 2021-08-30 IL IL300736A patent/IL300736A/en unknown
- 2021-08-31 CA CA3190441A patent/CA3190441A1/en active Pending
- 2021-08-31 EP EP21790626.2A patent/EP4204417A1/en active Pending
- 2021-08-31 WO PCT/US2021/048317 patent/WO2022047347A1/en active Application Filing
- 2021-08-31 AU AU2021334388A patent/AU2021334388A1/en active Pending
- 2021-08-31 AR ARP210102441A patent/AR123385A1/es unknown
- 2021-08-31 US US18/019,885 patent/US20230286973A1/en active Pending
- 2021-08-31 BR BR112023003265A patent/BR112023003265A2/pt unknown
- 2021-08-31 PE PE2023000533A patent/PE20231436A1/es unknown
- 2021-08-31 TW TW110132273A patent/TW202227428A/zh unknown
- 2021-08-31 CN CN202180052580.7A patent/CN116194455A/zh active Pending
- 2021-08-31 JP JP2023507944A patent/JP2023539553A/ja active Pending
- 2021-08-31 MX MX2023002288A patent/MX2023002288A/es unknown
- 2021-08-31 KR KR1020237009724A patent/KR20230058655A/ko unknown
-
2023
- 2023-02-27 CO CONC2023/0002202A patent/CO2023002202A2/es unknown
- 2023-02-28 CL CL2023000582A patent/CL2023000582A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116194455A (zh) | 2023-05-30 |
| JP2023539553A (ja) | 2023-09-15 |
| TW202227428A (zh) | 2022-07-16 |
| EP4204417A1 (en) | 2023-07-05 |
| US20230286973A1 (en) | 2023-09-14 |
| CA3190441A1 (en) | 2022-03-03 |
| KR20230058655A (ko) | 2023-05-03 |
| BR112023003265A2 (pt) | 2023-05-02 |
| CO2023002202A2 (es) | 2023-03-27 |
| IL300736A (en) | 2023-04-01 |
| AR123385A1 (es) | 2022-11-23 |
| WO2022047347A1 (en) | 2022-03-03 |
| CL2023000582A1 (es) | 2023-09-29 |
| MX2023002288A (es) | 2023-03-10 |
| AU2021334388A1 (en) | 2023-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119424A1 (es) | Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
| PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
| AR115885A1 (es) | Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno | |
| CL2022001392A1 (es) | Compuestos tricíclicos sustituidos | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| MX2022005839A (es) | Compuestos utiles como inhibidores de la proteina helios. | |
| DOP2017000310A (es) | Inhibidores de metalo-beta-lactamasa | |
| PE20211782A1 (es) | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| PE20191495A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| BR112016002287A2 (pt) | compostos terapeuticamente ativos e seus métodos de uso | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| MX2022007130A (es) | Derivados de piperazina sustituidos utiles como activadores de celulas t. | |
| MX2022011601A (es) | Compuestos de oxoisoindolina sustituidos para el tratamiento del cancer. | |
| MX2022007842A (es) | Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t. | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| AR114369A1 (es) | Dinucleótidos cíclicos como agentes antineoplásicos | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| PE20231436A1 (es) | Inhibidores de la secrecion de proteinas | |
| PE20231651A1 (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf | |
| AR091490A1 (es) | Antagonistas de iap | |
| EP4233865A3 (en) | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers |